ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia - Episode 10
Relapse After Venetoclax-Based Therapy: Early vs Late Management
Panelists review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy, managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy and defining early versus late relapse.
Video Player is loading.
Video content above is prompted by the following:
- Briefly review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy. (ESMO CLL Guideline Update 2024)
- Briefly comment on the underlying rationale and supporting data (high level) for continuous BTKi therapy in this setting.
- ALPINE – Brown, et al. ASH 2023. Abstract 202
- ELEVATE-RR– Seymour, et al. Blood. 2023
- How do you incorporate these data and recommendations into your treatment approach?
Late Relapse After 1L Venetoclax
- Briefly review recent ESMO guideline updates for managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy.
- How do you define early versus late relapse, and how does your treatment approach differ for each following venetoclax-based time-limited therapy?
- At what point do you consider retreatment with venetoclax?
